Biotech-Insider retweeted
Potential DNA damage from #CRISPR has been ‘seriously underestimated,’ study finds statnews.com/2018/07/16/cris… via @statnews #NBTintheNews
Biotech-Insider retweeted
New approach to #immunotherapy leads to complete response in breast cancer patient
medicalxpress.com/news/2018-… #BCSM #ASCO18
Finally had time to check out Steven Rosenberg's new TIL paper.
Really amazing scans!
nature.com/articles/s41591-0…
Biotech-Insider retweeted
In biotech, $6 billion can vanish quickly wsj.com/articles/in-biotech-…
Biotech-Insider retweeted
Bluebird, Celgene add another promising chapter to their success story with BCMA-targeting CAR-T bb2121
#ASCO18 $CELG $BLUE
endpts.com/bluebird-celgene-…
Biotech-Insider retweeted
$BLUE $CELG CAR-T delays multiple myeloma progression by one year, but is that enough? statnews.com/2018/06/01/blue… #ASCO18
Biotech-Insider retweeted
Replying to @_B_I_O_T_E_C_H_
Biotech-Insider retweeted
4 Powerful SEO Tips to Fast-track Your Biotech Business To The Top #biotechSEO #lifeScienceSEO #biotechWeb https://teapawt.org/t.co/EuONXfcBY6
Biotech-Insider retweeted
House passes Trump-backed drug bill, letting sick patients bypass FDA
politico.com/story/2018/05/2…
Biotech-Insider retweeted
FDA plans to speed path to approval for some gene therapies, starting with hemophilia statnews.com/2018/05/22/fda-… via @ikeswetlitz $BMRN $ONCE $QURE $PFE
Biotech-Insider retweeted
The FDA has approved a preventive treatment option for migraine patients cnn.it/2Lcq2Na
Biotech-Insider retweeted
The Biotech Forum: $DVAX $IMDZ $TGTX 3 Small Oncology Stocks That Could Get An "ASCO" Boost Next Week… dlvr.it/PGZkl3 #MedicBoard
Biotech-Insider retweeted
Biotech-Insider retweeted
Forget Amazon, Apple, and Intel. These biotech companies are the next Silicon Valley darlings trib.al/jCA9KZI
Biotech-Insider retweeted
FDA approval decision on Keytruda combination expected by late September dlvr.it/QRG59X MARKETWATCH
Biotech-Insider retweeted
The @US_FDA has accepted for priority review the Biologics License Application for cemiplimab for patients with metastatic cutaneous squamous cell carcinoma. The target action date for the FDA decision on the @Regeneron / @sanofi drug is October 28, 2018.
raredr.com/link/3395
Biotech-Insider retweeted
Biotech-Insider retweeted
Jefferies: 4 biotech stocks to buy that could be acquired within the next 18 months $AVXS $TGTX $NBIX $RIGL 247wallst.com/healthcare-bus…
Biotech-Insider retweeted
It's time to trade some biotechs. buff.ly/2DMJF9G





















